The 2018 Global Market for Transthyretin Amyloidosis (ATTR): Overview & Outlook (2016-2027) - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 7, 2018--The “Transthyretin Amyloidosis (ATTR) - Global Market Insights, Epidemiology and Forecast to 2027” drug pipelines has been added to ResearchAndMarkets.com’s offering.
According to the report, total prevalent population of ATTR in the 7 major markets ranges from approximately 19,197 cases in 2016, growing during the study period [2016-2027].
The report also estimates higher prevalence of ATTR in the Italy with 2,044 cases in 2016 followed by France. On the other hand, United Kingdom has the lowest prevalent population in 2016.
The report estimates that the diagnosed prevalent population of ATTR will significantly increase during the study period [2016-2027].
Hereditary transthyretin amyloidosis (hATTR) cases are segmented in to two segments which includes Familial Amyloid Polyneuropathy (FAP) and Familial Amyloid Cardiomyopathy (FAC) cases. In 2016, there were 5,201 cases of Familial Amyloid Polyneuropathy and of Familial Amyloid Cardiomyopathy in the 7MM.
FDA has approved few drugs such as Vyndaqel (Pfizer Inc), Onpattro (Alnylam Pharmaceuticals), Tegsedi (Ionis Pharmaceuticals /Akcea Therapeutics) which are used for the treatment of Transthyretin Amyloidosis (ATTR).
Key players such as Corino Therapeutics are involved in developing therapies for Transthyretin Amyloidosis (ATTR).
Expected launch of emerging therapies such as CRX-1008: Corino Therapeutics therapies will significantly impact the Transthyretin Amyloidosis (ATTR) market during the study period (2016-2027).
This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Transthyretin Amyloidosis (ATTR) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Transthyretin Amyloidosis (ATTR) from 2016 to 2027 segmented by seven major markets.
The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Companies FeaturedAlnylam Pharmaceuticals Corino Therapeutics Ionis Pharmaceuticals/Akcea Therapeutics Pfizer Inc.
Key Topics Covered
1. Key Insights
2. Transthyretin Amyloidosis (ATTR): Overview at a Glance
3. Transthyretin-Related Amyloidosis: Disease Background and Overview
4. Epidemiology and Patient Population
5. Epidemiology by Country
6. 7MM Diagnosed Prevalent and Surgery Cases of ATTR Related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
8. Unmet Needs
9. Marketed Drugs
10. Emerging Therapies
11. Transthyretin Amyloidosis: Market Analysis
12. Transthyretin Amyloidosis: 7 Major Market Outlook
13. Market Outlook by Country
14. Market Drivers
15. Market Barriers
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/dhjmv7/the_2018_global?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181207005355/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs ,Endocrine and Metabolic Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 12/07/2018 11:11 AM/DISC: 12/07/2018 11:11 AM